4basebio (LON:4BB) Stock Jumps 3.5% – Time to Buy?

4basebio PLC (LON:4BB)’s share price rose 3.5% during mid-day trading on Tuesday. The stock traded as high as GBX 543.30 and last traded at GBX 543.30. 18 shares traded hands during mid-day trading, a decline of 99% from the average daily volume of 1,301 shares. The stock had previously closed at GBX 525.

4basebio Stock Down 4.5%

The firm has a market capitalization of £81.34 million, a P/E ratio of -4.53 and a beta of 1.09. The firm’s 50-day moving average is GBX 518.99 and its 200 day moving average is GBX 514.40. The company has a debt-to-equity ratio of 201.47, a quick ratio of 3.52 and a current ratio of 2.73.

4basebio (LON:4BB) last announced its quarterly earnings data on Monday, September 28th. The company reported GBX (0.57) earnings per share (EPS) for the quarter. As a group, equities research analysts predict that 4basebio PLC will post -3.43 EPS for the current fiscal year.

4basebio Company Profile

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients.

Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.